多巴丝肼与复方卡比多巴治疗早期帕金森病患者的疗效比较<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2025.08.003

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1276 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To compare the efficacy and safety of levodopa-benserazide and compound carbidopa in the treatment of patients with early Parkinson's disease (PD).【Methods】 A total of 180 PD patients were randomly divided into the observation group and the control group, with 90 cases in each group. The control group was treated with levodopa-benserazide, while the observation group was treated with compound carbidopa. The efficacy, incidence of adverse reactions, and changes in scores of Part Ⅱ (daily activities, UPDRSⅡ) and Part Ⅲ (motor function, UPDRSⅢ) of the Unified Parkinson's Disease Rating Scale (UPDRS) and Parkinson's Disease Questionnaire-39 (PDQ-39) before and after treatment were compared between the two groups.【Results】After 12 weeks of treatment, there was no significant difference in the total effective rate between the two groups (P>0.05). From pre-treatment to 12 weeks after treatment, the scores of UPDRSⅡ, UPDRSⅢ, and PDQ-39 in both groups gradually decreased with the extension of time, and the differences at each time point were statistically significant (P<0.05). There were no significant differences in UPDRSⅡ, UPDRSⅢ, and PDQ-39 scores between the two groups before and at each time point after treatment (P>0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).【Conclusion】The efficacy of levodopa-benserazide tablets and compound carbidopa in the treatment of early PD is comparable, however, compound carbidopa has higher safety.

Key words： Parkinson Disease Hydrazines Carbidopa Treatment Outcome

Received: 07 May 2025

PACS:

R741

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.08.003 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I8/1304

[1] 姚甲瑞,杨扬,王娜,等.运动康复频率对帕金森病患者症状及生活质量的影响[J].中华老年心脑血管病杂志,2025,27(6):717-721.
[2] 韩雨薇,郝广志,霍达,等. 1990-2021年中国老年人群帕金森病发病率变化趋势分析及预测研究 [J].中国循证医学杂志, 2025,25(6):647-652.
[3] 赵乾,李海涛,霍孜克,等.STN-DBS联合小剂量多巴丝肼治疗帕金森病的疗效及对抑郁症状、脑功能连接的影响[J].中南医学科学杂志,2025,53(4):656-659.
[4] 钟彩琴,吕俊杰.卡比多巴-左旋多巴控释片治疗帕金森病合并睡眠障碍效果观察[J].中国实用医药,2018,13(27):134-135.
[5] 陈生弟, 陈海波. 中国帕金森病治疗指南(第四版)[J].中华神经科杂志, 2020,53(12):973-986.
[6] 史靖,胡军,罗开亮,等. 帕金森病患者ApoA-1水平与UPDRS评分、MMSE评分及脑白质微结构改变的关系[J].分子诊断与治疗杂志,2022,14(3):422-425.
[7] 高源,田凤. 血清YKL-40、Hcy、UA及BDNF水平与帕金森病患者认知功能的相关性研究[J].医学临床研究,2025,42(1):23-26.
[8] 肖雪洋,胡琳珍.帕金森发病机制及其最新治疗策略[J].湖北大学学报(自然科学版),2021,43(5):514-521.
[9] 温广鑫, 闫磊, 刘卫国, 等. 复方卡比多巴和多巴丝肼的药代动力学和药效学比较研究[J].中国临床药理学杂志, 2024,40(2):254-258.
[10] 郭珍. 多巴丝肼联合左旋多巴治疗帕金森病的效果及对血清炎症因子的影响[J].中国医学创新, 2023,20(2):32-36.
[11] 庄艳华,宋阳.普拉克索联合多巴丝肼治疗帕金森病的临床效果及对患者相关评分的影响[J].临床合理用药,2024,17(29):41-44.
[12] 吴晓燕,陈遥,陈晓仪,等.恩他卡朋联合卡比多巴治疗帕金森病的临床效果[J].临床合理用药,2024,17(15):12-15.
[13] 关晶,童欣,张怡,等. 沙格雷酯和卡比多巴联合用药对顺铂诱导小鼠急性肾损伤的保护作用[J].中国药理学与毒理学杂志,2021,35(4):275-282.
[14] 郭辉,寻明金,冯中,等. 卡比多巴左旋多巴缓释片的研制及药效学评价[J].中国医药工业杂志,2022,53(6):862-867.